Annovis Bio : ANVS

ANVS

Stock Data

$2.00

$0.03 (1.52%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.

All Annovis Bio Articles

1 Article

John Seetoo | Mar 15, 2024 at 9:11 AM EDT

$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year

Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form…

Annovis Bio : ANVS

ANVS

$2.00

All Annovis Bio Articles

$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Annovis Bio : ANVS

ANVS

$2.00

All Annovis Bio Articles

$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026